TOKYO, Japan & MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Type II ...
If approved, AQNEURSA® would become the first approved therapy for Ataxia-Telangiectasia in the European Economic Area IntraBio Inc. today announced the submission of a variation application to the ...
IntraBio Inc. today announced the submission of a variation application to the European Medicines Agency (EMA) to expand the approved Marketing Authorization Application (MAA) for AQNEURSA ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results